A Phase I/II Trial of Inotuzumab Ozogamicin in Combination with Low-Intensity Chemotherapy as Frontline Therapy for Older Patients with ALL

The outcome of elderly patients with acute lymphoblastic leukemia (ALL) is poor. Combinations of novel agents, such as the anti-CD22 drug-antibody conjugate inotuzumab ozogamicin (INO), with reduced intensity chemotherapy may improve outcomes.

Source: Clinical Lymphoma, Myeloma and Leukemia - August 26, 2016 Category: Hematology Authors: Nicholas Short, Elias Jabbour, Susan O'Brien, Rita Khouri, Farhad Ravandi, Deborah Thomas, Guillermo Garcia-Manero, Koji Sasaki, Gautam Borthakur, Nitin Jain, Marina Konopleva, Jovitta Jacob, Rebecca Garris, Jorge Cortes, Hagop Kantarjian Source Type: research